At Large: Why Didn’t Novartis Try to Conceal its Ongoing Bribery?

While not excusing the company’s misconduct, Richard Cassin expresses amazement that Swiss pharma giant Novartis didn’t do a better job of keeping its illegal behavior secret. Cassin notes that nearly everything the company did to violate the FCPA was done openly, with none of the expected subterfuge to cover it up. He speculates at reasons: […]
Must be a Paid Member or a Free Trial Member to Access Content. Members log in here.